Pluristyx Analysis
What is Pluristyx?
mRNA-reprogrammed iPSCs for accelerated cell therapy development
Location
Seattle, United States
Employees
11-50
Founded
2018
Product Features & Capabilities
- RTD® iPSC & GMP Cell Banks
- PluriBank™
- PluriForm™ Organoid Kit
- PluriFreeze™
- PluriKit™
- Custom iPSCs
- Differentiated Cells
- FailSafe® gene editing
- iACT Stealth Cells™
- GMP Manufacturing
- Consumables
Use Cases
Develop gene-edited iPSC therapies with FailSafe® edit; Access clinical-grade iPSCs for preclinical studies; Generate organoid models for disease modeling; Scale up cell production using RTD® cell banks; Perform custom gene editing for therapeutic applications; Manufacture GMP-compliant cell products; Utilize iACT Stealth Cells™ for immune evasion
Other Considerations
Completed $10M investment round in July 2025; Strategic partnerships with Solesis and BioLamina; Recognized as leading provider of iPSC technologies; Offers end-to-end support from derivation to commercialization; Provides proprietary FailSafe® gene editing platform with functional control
See something that needs updating? Suggest edits to this profile.